Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 23 | 2017 | 362 | 2.140 |
Why?
|
| Brain Neoplasms | 18 | 2019 | 647 | 1.300 |
Why?
|
| Gamma Rays | 3 | 2015 | 25 | 0.570 |
Why?
|
| Radiometry | 4 | 2015 | 40 | 0.530 |
Why?
|
| Radiation Oncology | 2 | 2013 | 13 | 0.500 |
Why?
|
| Meningioma | 4 | 2014 | 58 | 0.470 |
Why?
|
| Societies, Scientific | 1 | 2013 | 15 | 0.410 |
Why?
|
| Molecular Imaging | 1 | 2013 | 20 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2014 | 1308 | 0.400 |
Why?
|
| Meningeal Neoplasms | 3 | 2014 | 50 | 0.380 |
Why?
|
| Brain | 5 | 2015 | 949 | 0.370 |
Why?
|
| Cranial Irradiation | 5 | 2017 | 93 | 0.370 |
Why?
|
| Burns | 1 | 2012 | 100 | 0.350 |
Why?
|
| Models, Animal | 1 | 2011 | 173 | 0.340 |
Why?
|
| Skin | 1 | 2012 | 214 | 0.330 |
Why?
|
| Salvage Therapy | 6 | 2015 | 134 | 0.320 |
Why?
|
| Whole-Body Irradiation | 5 | 2015 | 55 | 0.300 |
Why?
|
| Radiation Injuries | 4 | 2017 | 78 | 0.240 |
Why?
|
| Nomograms | 3 | 2015 | 35 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2015 | 384 | 0.230 |
Why?
|
| Carmustine | 1 | 2015 | 8 | 0.220 |
Why?
|
| Male | 28 | 2017 | 19743 | 0.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 40 | 0.220 |
Why?
|
| Trigeminal Neuralgia | 2 | 2015 | 33 | 0.220 |
Why?
|
| Middle Aged | 21 | 2017 | 12202 | 0.210 |
Why?
|
| Humans | 30 | 2019 | 32952 | 0.210 |
Why?
|
| Treatment Outcome | 13 | 2017 | 3460 | 0.210 |
Why?
|
| Female | 27 | 2019 | 20363 | 0.210 |
Why?
|
| Retrospective Studies | 13 | 2015 | 3708 | 0.210 |
Why?
|
| Animals | 16 | 2019 | 7598 | 0.200 |
Why?
|
| Aged | 18 | 2017 | 10624 | 0.200 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2015 | 36 | 0.190 |
Why?
|
| Adult | 17 | 2017 | 9586 | 0.190 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 754 | 0.190 |
Why?
|
| Radiotherapy Dosage | 7 | 2017 | 99 | 0.180 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 429 | 0.170 |
Why?
|
| Treatment Failure | 6 | 2015 | 156 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2015 | 370 | 0.160 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.150 |
Why?
|
| Macaca mulatta | 3 | 2017 | 319 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.150 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1015 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2014 | 4057 | 0.140 |
Why?
|
| Aging | 2 | 2014 | 945 | 0.130 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2287 | 0.130 |
Why?
|
| Calcium | 1 | 2019 | 323 | 0.130 |
Why?
|
| Radiation Dosage | 3 | 2012 | 84 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 50 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 22 | 0.120 |
Why?
|
| Brain Injuries | 1 | 2017 | 92 | 0.120 |
Why?
|
| Phantoms, Imaging | 2 | 2015 | 59 | 0.120 |
Why?
|
| Epilepsy | 1 | 2017 | 83 | 0.120 |
Why?
|
| Calibration | 2 | 2015 | 28 | 0.120 |
Why?
|
| Facial Pain | 2 | 2014 | 21 | 0.120 |
Why?
|
| Pain Measurement | 2 | 2014 | 356 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 13 | 0.110 |
Why?
|
| Melanoma | 2 | 2015 | 165 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 30 | 0.110 |
Why?
|
| Brain Edema | 1 | 2014 | 16 | 0.110 |
Why?
|
| X-Rays | 2 | 2011 | 6 | 0.110 |
Why?
|
| Growth Hormone | 2 | 2013 | 15 | 0.110 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 4 | 0.110 |
Why?
|
| Dog Diseases | 1 | 2013 | 12 | 0.100 |
Why?
|
| Survival Rate | 5 | 2017 | 895 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 22 | 0.100 |
Why?
|
| Vein of Galen Malformations | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cerebral Veins | 1 | 2013 | 11 | 0.100 |
Why?
|
| Health Physics | 1 | 2013 | 4 | 0.100 |
Why?
|
| Radiobiology | 1 | 2013 | 5 | 0.100 |
Why?
|
| Brain Death | 1 | 2013 | 27 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2012 | 205 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 576 | 0.090 |
Why?
|
| Radio Waves | 1 | 2012 | 7 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 26 | 0.090 |
Why?
|
| Temperature | 1 | 2012 | 51 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 16 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2019 | 604 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 18 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 158 | 0.090 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 5 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 770 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 765 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 326 | 0.090 |
Why?
|
| Collagen Diseases | 1 | 2011 | 5 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2013 | 486 | 0.090 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 432 | 0.090 |
Why?
|
| Nanotubes, Carbon | 1 | 2011 | 23 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 300 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 35 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 412 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2011 | 68 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 116 | 0.080 |
Why?
|
| Time Factors | 5 | 2014 | 2195 | 0.080 |
Why?
|
| Iron | 1 | 2011 | 116 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2011 | 60 | 0.080 |
Why?
|
| Cognition | 1 | 2014 | 553 | 0.080 |
Why?
|
| Hippocampus | 1 | 2011 | 171 | 0.080 |
Why?
|
| Etidronic Acid | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mice | 5 | 2019 | 2528 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 23 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2015 | 82 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2014 | 61 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2011 | 157 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2009 | 82 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2009 | 94 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2009 | 71 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 475 | 0.070 |
Why?
|
| Osteoclasts | 1 | 2008 | 25 | 0.070 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 241 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2008 | 81 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2008 | 10 | 0.070 |
Why?
|
| Rats | 4 | 2014 | 1610 | 0.070 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2007 | 15 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 61 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 36 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 64 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 727 | 0.070 |
Why?
|
| Ovary | 1 | 2007 | 59 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 599 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 112 | 0.060 |
Why?
|
| Rats, Inbred F344 | 3 | 2013 | 134 | 0.060 |
Why?
|
| Child | 3 | 2014 | 2478 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 155 | 0.060 |
Why?
|
| Young Adult | 4 | 2014 | 2738 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 950 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 319 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2011 | 1469 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 476 | 0.050 |
Why?
|
| Algorithms | 1 | 2008 | 517 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 282 | 0.050 |
Why?
|
| Cause of Death | 2 | 2015 | 240 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 563 | 0.050 |
Why?
|
| Stereotaxic Techniques | 2 | 2014 | 23 | 0.050 |
Why?
|
| Radiography | 2 | 2015 | 386 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 3643 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 790 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 2 | 2013 | 33 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1246 | 0.040 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 28 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 65 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 98 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 497 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 392 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 2338 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 23 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 117 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 80 | 0.030 |
Why?
|
| Air | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hypesthesia | 1 | 2015 | 9 | 0.030 |
Why?
|
| United States | 2 | 2015 | 4132 | 0.030 |
Why?
|
| Water | 1 | 2015 | 61 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 91 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 21 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 48 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 101 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2015 | 162 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2014 | 11 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 260 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 30 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 129 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 20 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2013 | 9 | 0.030 |
Why?
|
| Dogs | 1 | 2013 | 120 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 195 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 87 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 500 | 0.030 |
Why?
|
| History, 18th Century | 1 | 2013 | 2 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 37 | 0.020 |
Why?
|
| Pain | 1 | 2015 | 296 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 61 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 83 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 113 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 682 | 0.020 |
Why?
|
| Organ Size | 1 | 2013 | 220 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 194 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 82 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 51 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 168 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 106 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 11 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 65 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 38 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 193 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2011 | 12 | 0.020 |
Why?
|
| Ectodysplasins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1852 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2011 | 11 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2011 | 16 | 0.020 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2011 | 20 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2011 | 56 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 47 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 40 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 471 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 105 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 34 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 23 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 80 | 0.020 |
Why?
|
| Microglia | 1 | 2011 | 68 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 139 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 290 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 24 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 148 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 169 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 460 | 0.020 |
Why?
|
| Glioma | 1 | 2011 | 136 | 0.020 |
Why?
|
| Primates | 1 | 2010 | 118 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 248 | 0.020 |
Why?
|
| Systems Integration | 1 | 2009 | 11 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1282 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2009 | 20 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1002 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 894 | 0.020 |
Why?
|
| Artifacts | 1 | 2009 | 42 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 77 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 565 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 469 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 363 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 27 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2008 | 70 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 828 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 4001 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 821 | 0.020 |
Why?
|